HopeStage
Back to all studies
CompletedNCT06058013

NMRA-335140 compared with placebo for depression

About this titleRead the official source — NCT06058013

Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Encino and 73 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 20, 2023
Recruitment status
Completed
Enrollment listed in the registry
430
Sponsor
Neumora Therapeutics, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada, Brazil, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT06058013
Official title
Show the full official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Encino, United States · Garden Grove, United States · Los Alamitos, United States

55 more locations
  • Newport Beach, United States
  • Orange, United States
  • Santa Ana, United States
  • Norwalk, United States
  • Bradenton, United States
  • Hollywood, United States
  • Homestead, United States
  • Lauderhill, United States
  • Maitland, United States
  • Miami, United States
  • Miami Lakes, United States
  • Orlando, United States
  • Pinellas Park, United States
  • Pompano Beach, United States
  • Tampa, United States
  • Atlanta, United States
  • Marrero, United States
  • New Orleans, United States
  • Baltimore, United States
  • Towson, United States
  • Boston, United States
  • Watertown, United States
  • Mankato, United States
  • Princeton, United States
  • Toms River, United States
  • Albuquerque, United States
  • Buffalo, United States
  • Inwood, United States
  • New York, United States
  • The Bronx, United States
  • Monroe, United States
  • North Canton, United States
  • Edmond, United States
  • Oklahoma City, United States
  • Philadelphia, United States
  • North Charleston, United States
  • Memphis, United States
  • Austin, United States
  • Dallas, United States
  • Houston, United States
  • Bellevue, United States
  • Everett, United States
  • Curitiba, Brazil
  • Porto Alegre, Brazil
  • Santa Cecília, Brazil
  • São Bernardo do Campo, Brazil
  • São José do Rio Preto, Brazil
  • Rio de Janeiro, Brazil
  • São Paulo, Brazil
  • Kelowna, Canada
  • Hamilton, Canada
  • Markham, Canada
  • Toronto, Canada
  • Santiago, Chile
  • Antofagasta, Chile

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.

Who is behind this study?

The study sponsor is Neumora Therapeutics, Inc.

Did this study involve medication?

Yes. The study involved medication, including NMRA-335140 and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies